Status:
RECRUITING
Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
Lead Sponsor:
Medical University of Graz
Conditions:
Bee Venom Allergy
Eligibility:
All Genders
18-70 years
Brief Summary
Venom immunotherapy (VIT) is an established treatment for Hymenoptera venom allergy and provides long-term protection from further generalized reactions in almost all patients. However, it is still un...
Eligibility Criteria
Inclusion Criteria:
- Legally competent male and female subjects aged from 18 to 70 years with a history of a systemic anaphylactic sting reaction (≥ grade I according to the classification of Ring and Messmer) after bee stings, who will receive bee venom immunotherapy
Exclusion Criteria:
- Contraindications to VIT
Key Trial Info
Start Date :
May 2 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
266 Patients enrolled
Trial Details
Trial ID
NCT04259359
Start Date
May 2 2019
End Date
March 1 2026
Last Update
December 8 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology and Venerology, Medical University of Graz
Graz, Austria, 8036
2
Elbe Klinikum Buxtehude
Buxtehude, Germany, 21614
3
Hospital Universitario de Castellón
Castellon, Spain, 12004